InnoStar

InnoStar has the industry-leading international service capability and provides one-stop new drug research and development services that are compliant with domestic and international application standards for global pharmaceutical companies and research institutions. After years of development, InnoStar now has built up nearly 60,000 square meters of modern laboratory and test facilities, employing over one thousand scientists and professional technicians in Shanghai, Nantong, Shenzhen, Huangshan, and USA. 1. Relevant Qualification Over the past decade, InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification form the National Medical Products Administration (NMPA), OECD GLP certification from the Netherlands GLP monitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. 2. Business scope Our business scope covers early-stage druggability assessment, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, and biomarkers and translational research. 3. Service experience We have completed over 13,700 projects for more than 770 sponsors. These studies have been submitted in support of over 370 INDs and 18 NDAs/BLAs for innovative drugs in China and 2 NDAs/BLAs in the United States, over 90 INDs in the United States, the European Union, South Korea, and Australia, etc. Data updated to: Dec 31, 2023 InnoStar is committed to providing one-stop service solutions to our sponsors in China and abroad. We are striving to be the scientific and technological innovation pioneer, new drug R&D accelerator, and human life and health guardian. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).